Pharol, SGPS S.A (PHR) Fair Value & Analysis
Healthcare · PT · Market cap 35.4M PLN
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 5 days ago
Share price −1.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 2.56 PLN – 4.23 PLN · fair‑value band 2.92 PLN – 4.87 PLN · the 3.18 PLN price screens below the 3.90 PLN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pharol, SGPS S.A (PHR) currently trades at 3.18 PLN, while our model-based Fair Value estimate is 3.90 PLN — implying the stock looks roughly 22.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at 1.6M PLN. It earns a return on equity of -25.1%. The balance sheet holds a net cash position of 1.5M PLN. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Pharol, SGPS S.A., through its investment in Oi, S.A., engages in the provision of telecommunications services in Brazil. It is also involved in the management of shareholdings in other companies. The company was formerly known as Portugal Telecom, SGPS, SA and changed its name to Pharol, SGPS S.A. in May 2015. Pharol, SGPS S.A. was incorporated in 1994 and is headquartered in Lisbon, Portugal.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharol, SGPS S.A reported revenue of 1.6M PLN in FY2025 versus 15.2M PLN in FY2021, a compound −43.3%/yr. Reported net income was −2.8M PLN in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $612.50 | $1,280 | +109% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharol, SGPS S.A (PHR) undervalued?
What is the fair value of PHR?
What is the quality score of PHR?
What is the revenue of Pharol, SGPS S.A (PHR)?
What is the net profit margin of PHR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.